Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis
David A. Palma(Western University), George Rodrigues(London Health Sciences Centre), Sara Ramella(Università Campus Bio-Medico), Marta Moreno(Clinica Universidad de Navarra), R. Bryan Barriger(Indiana University – Purdue University Indianapolis), Kayoko Tsujino(Hyogo Prefectural Cancer Center), Luigi De Petris(Karolinska University Hospital), Larry Stitt(Western University), Suresh Senan(Amsterdam Neuroscience), Lawrence B. Marks(University of North Carolina at Chapel Hill), Jeffrey D. Bradley(Hospital of the University of Pennsylvania), Tae Hyun Kim(Sookmyung Women's University), Ramesh Rengan(University of Pennsylvania)
International Journal of Radiation Oncology*Biology*Physics
January 9, 2013
Cited by 673
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k